rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
|
25370471 |
2015 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
|
17309670 |
2007 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer.
|
20735442 |
2011 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
|
25370471 |
2015 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In addition, our work also points out the importance of new studies for Lys751Gln association in endometrial cancer and ovarian cancer, where at least some of the covariates responsible for heterogeneity could be controlled, to obtain a more conclusive understanding about the function of the Lys751Gln polymorphism in cancer development.
|
25113251 |
2014 |
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.
|
27863412 |
2016 |
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The present study suggests that the ERCC2 gene rs13181 polymorphism might be associated with increased risk of ovarian cancer.
|
28676967 |
2017 |
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
There are no associations between the XPC PAT+/-, XRCC1 Arg194Trp, Arg280His, Arg399Gln, and XPD Asp312Asn, Lys751Gln polymorphisms and the survival of patients with epithelial ovarian cancer when treated with platinum-based chemotherapy.
|
23621265 |
2013 |
rs13181
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the role of SNPs in three genes, XRCC2 (R188H), ERCC2 (K751Q) and CDKN1B (V109G) which are with moderate risk for ovarian cancer susceptibility in Egyptian women.
|
23277402 |
2013 |
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer.
|
12370157 |
2002 |
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We found no effect of N314D GALT genotype on the risk of borderline ovarian cancer (odds ratio (OR)=0.91; 95% confidence interval (CI)=0.54-1.6) or invasive ovarian cancer (OR=0.78; 95% CI= 0.53-1.2).
|
11936817 |
2002 |
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We conclude that the GALT N314D allele does not predispose to epithelial ovarian cancer.
|
12869412 |
2003 |
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The difference was most evident for endometrioid and clear cell types of ovarian cancer, in which 3.9% of cases were found to be homozygous for N314D compared with 0.4% of controls, yielding an odds ratio and 95% confidence interval of 14.17 (2.62-76.60).
|
10667469 |
2000 |
rs2070074
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Our results support previous reports of an association of impaired galactose metabolism with serous and undifferentiated ovarian cancers but contradict previous findings of increased N314D mutation frequencies among women with endometriosis and endometrioid and clear cell sub-types ovarian cancer.
|
9714048 |
1998 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The rs2228570 polymorphism increased the risk of ovarian cancer in Caucasian populations in a dominant genetic model.
|
29239065 |
2018 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
More studies are warranted to assess the association between the VDR rs2228570 polymorphism and ovarian cancer in Asians and Africans.
|
24136742 |
2014 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
This pooled analysis provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer susceptibility.
|
20473893 |
2011 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The homozygote model with the rs2228570 (FokI) polymorphism model appeared to detect the risk of OC in all cases, whereas the heterozygote model with the rs1544410 (BsmI) polymorphism seemed to detect the risk of OC in Caucasian patients.
|
30059751 |
2018 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The VDR polymorphism FokI (rs2228570) seems to increase the risk of ovarian cancer.
|
29113037 |
2017 |
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cumulative risk analysis revealed 3 unfavorable variants that increased significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR 7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008).
|
25591549 |
2015 |
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion SNPs in WRAP53 (rs2287497 and rs2287498) have stronger association with an ovarian cancer risk than rs1042522 in TP53.
|
23192612 |
2013 |